Last updated: 2 July 2024 at 1:27pm EST

Paul Clancy Net Worth




The estimated Net Worth of Paul J Clancy is at least $17.8 million dollars as of 20 May 2022. Mr. Clancy owns over 1,585 units of Incyte stock worth over $413,438 and over the last 17 years he sold INCY stock worth over $16,820,553. In addition, he makes $536,489 as Independent Director at Incyte.

Mr. Clancy INCY stock SEC Form 4 insiders trading

Paul has made over 29 trades of the Incyte stock since 2008, according to the Form 4 filled with the SEC. Most recently he exercised 1,585 units of INCY stock worth $100,061 on 20 May 2022.

The largest trade he's ever made was exercising 99,030 units of Incyte stock on 16 September 2013 worth over $5,556,573. On average, Paul trades about 2,993 units every 46 days since 2007. As of 20 May 2022 he still owns at least 6,549 units of Incyte stock.

You can see the complete history of Mr. Clancy stock trades at the bottom of the page.





Paul Clancy biography

Paul J. Clancy is an Independent Director of Incyte Corporation. Mr. Clancy has more than 30 years of experience in financial management and strategic business planning, and has served as the Executive Vice President and Chief Financial Officer of Alexion Pharmaceuticals, Inc., a biopharmaceutical company, since July 2017. Prior to joining Alexion, Mr. Clancy served as Executive Vice President, Finance and Chief Financial Officer of Biogen Inc. (formerly known as Biogen Idec Inc.), a biotechnology company, from August 2007 until June 2017. He also served as Senior Vice President of Finance of Biogen, with responsibilities for leading the treasury, tax, investor relations and business planning groups. Prior to the 2003 merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation to form Biogen, Mr. Clancy was the Vice President of Portfolio Management of Biogen. He joined Biogen in 2001 as Vice President of U.S. Marketing. Before Biogen, Mr. Clancy spent 13 years at PepsiCo Inc., a food and beverage company, serving in a variety of financial and general management positions, including Vice President and General Manager of their Great West Business Unit.

What is the salary of Paul Clancy?

As the Independent Director of Incyte, the total compensation of Paul Clancy at Incyte is $536,489. There are 14 executives at Incyte getting paid more, with Herve Hoppenot having the highest compensation of $15,151,200.



How old is Paul Clancy?

Paul Clancy is 58, he's been the Independent Director of Incyte since 2015. There are 12 older and 12 younger executives at Incyte. The oldest executive at Incyte Corp. is Pamela M. Murphy, 70, who is the VP of Investor Relations & Corp. Communications.

What's Paul Clancy's mailing address?

Paul's mailing address filed with the SEC is 1801 AUGUSTINE CUT-OFF, , WILMINGTON, DE, 19803.

Insiders trading at Incyte

Over the last 21 years, insiders at Incyte have traded over $114,417,378 worth of Incyte stock and bought 24,211,970 units worth $713,884,116 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B... et Brothers Life Sciences Capi.... On average, Incyte executives and independent directors trade stock every 14 days with the average trade being worth of $4,355,654. The most recent stock trade was executed by Steven H Stein on 12 August 2024, trading 11,608 units of INCY stock currently worth $703,793.



What does Incyte do?

incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.



What does Incyte's logo look like?

Incyte Corp. logo

Complete history of Mr. Clancy stock trades at Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Biogen Inc, Exact Sciences et Incyte

Date
#
Société
Initié
Trans.
Transaction
Actions Prix par action Prix ​​total Actions après Source
20 May 2022 Paul J Clancy
Directeur
Exercice d'option 1,585 $21.10 $33,444
20 May 2022
6,549
28 May 2021 Paul J Clancy
Directeur
Exercice d'option 1,686 $55.78 $94,045
28 May 2021
4,964
28 May 2020 Paul J Clancy
Directeur
Exercice d'option 1,878 $53.35 $100,191
28 May 2020
3,278
10 Jul 2018 Paul J Clancy
Vice-président exécutif et Directeur financier
Vente 5,241 $131.11 $687,148
10 Jul 2018
93,309
6 Feb 2018 Paul J Clancy
Vice-président exécutif et Directeur financier
Vente 6,079 $116.31 $707,048
6 Feb 2018
89,014
25 Apr 2017 Paul J Clancy
Directeur des finances
Vente 9,892 $290.00 $2,868,680
25 Apr 2017
10,813
13 Mar 2017 Paul J Clancy
Directeur des finances
Vente 9,891 $291.55 $2,883,721
13 Mar 2017
20,705
28 Feb 2017 Paul J Clancy
Directeur des finances
Exercice d'option 6,780 $288.60 $1,956,708
28 Feb 2017
31,948
23 Feb 2016 Paul J Clancy
Directeur des finances
Exercice d'option 579 $258.99 $149,955
23 Feb 2016
27,143
12 Feb 2016 Paul J Clancy
Directeur des finances
Exercice d'option 3,859 $247.22 $954,022
12 Feb 2016
27,768
8 Feb 2016 Paul J Clancy
Directeur des finances
Exercice d'option 3,194 $250.77 $800,959
8 Feb 2016
25,451
12 Feb 2015 Paul J Clancy
Directeur des finances
Exercice d'option 4,299 $392.11 $1,685,681
12 Feb 2015
22,960
8 Feb 2015 Paul J Clancy
Directeur des finances
Exercice d'option 7,882 $402.00 $3,168,564
8 Feb 2015
22,194
23 Feb 2014 Paul J Clancy
Directeur des finances
Exercice d'option 4,280 $347.11 $1,485,631
23 Feb 2014
17,473
12 Feb 2014 Paul J Clancy
Directeur des finances
Exercice d'option 2,807 $323.04 $906,773
12 Feb 2014
14,517
8 Feb 2014 Paul J Clancy
Directeur des finances
Exercice d'option 7,882 $315.54 $2,487,086
8 Feb 2014
13,922
18 Sep 2013 Paul J Clancy
Directeur des finances
Exercice d'option 26,785 $49.65 $1,329,875
18 Sep 2013
33,872
16 Sep 2013 Paul J Clancy
Directeur des finances
Exercice d'option 99,030 $56.11 $5,556,573
16 Sep 2013
51,027
29 Apr 2013 Paul J Clancy
Directeur des finances
Vente 23,612 $222.75 $5,259,573
29 Apr 2013
7,087
23 Feb 2013 Paul J Clancy
Directeur des finances
Exercice d'option 4,281 $164.40 $703,796
23 Feb 2013
32,720
8 Feb 2013 Paul J Clancy
Directeur des finances
Exercice d'option 7,457 $164.44 $1,226,229
8 Feb 2013
30,170
23 Feb 2012 Paul J Clancy
Directeur des finances
Exercice d'option 4,281 $116.70 $499,593
23 Feb 2012
28,184
9 Feb 2012 Paul J Clancy
Directeur des finances
Exercice d'option 4,692 $117.78 $552,624
9 Feb 2012
25,860
1 Feb 2012 Paul J Clancy
Directeur des finances
Exercice d'option 21,400 $52.95 $1,133,130
1 Feb 2012
42,568
3 Jan 2012 Paul J Clancy
Directeur des finances
Vente 20,244 $112.35 $2,274,413
3 Jan 2012
21,168
28 Apr 2011 Paul J Clancy
Directeur des finances
Vente 19,716 $98.91 $1,950,110
28 Apr 2011
42,247
5 Mar 2011 Paul J Clancy
Directeur des finances
Exercice d'option 28,750 $58.99 $1,695,963
5 Mar 2011
73,085
21 Feb 2008 Paul J Clancy
Directeur des finances
Vente 2,183 $60.22 $131,460
21 Feb 2008
42,663
12 Feb 2008 Paul J Clancy
Directeur des finances
Vente 958 $60.96 $58,400
12 Feb 2008
30,173


Incyte executives and stock owners

Incyte executives and other stock owners filed with the SEC include: